Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Dyslipidemia

  Free Subscription


Articles published in Atherosclerosis

Retrieve available abstracts of 107 articles:
HTML format
Text format



Single Articles


    July 2018
  1. MARTIN SS
    Calculating LDL cholesterol in familial combined hyperlipidemia: Out with the old, in with the new?
    Atherosclerosis. 2018 Jul 27. pii: S0021-9150(18)31241.
    PubMed     Text format    


    June 2018
  2. ADEMI Z, Martin AC
    Universal screening of children for familial hypercholesterolaemia: Value for money?
    Atherosclerosis. 2018 Jun 22. pii: S0021-9150(18)31186.
    PubMed     Text format    


    May 2018
  3. MULLER HH
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study.
    Atherosclerosis. 2018 May 30. pii: S0021-9150(18)30260.
    PubMed     Text format    


  4. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Reply to: "Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study".
    Atherosclerosis. 2018 May 22. pii: S0021-9150(18)30261.
    PubMed     Text format    


    February 2018
  5. VITVEROVA B, Blazickova K, Najmanova I, Vicen M, et al
    Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta.
    Atherosclerosis. 2018;271:15-25.
    PubMed     Text format     Abstract available


  6. FOGACCI F, Cicero AFG
    Gene targeting for chylomicronemia syndrome: The brave new world.
    Atherosclerosis. 2018;269:254-255.
    PubMed     Text format    


    January 2018
  7. PELCZARSKA A, Jakubczyk M, Jakubiak-Lasocka J, Banach M, et al
    The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Atherosclerosis. 2018;270:132-138.
    PubMed     Text format     Abstract available


  8. RODRIGUEZ-BORJABAD C, Ibarretxe D, Girona J, Ferre R, et al
    Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia.
    Atherosclerosis. 2018;270:117-122.
    PubMed     Text format     Abstract available


  9. KAYIKCIOGLU M, Tokgozoglu L, Yilmaz M, Kaynar L, et al
    A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).
    Atherosclerosis. 2018;270:42-48.
    PubMed     Text format     Abstract available


  10. DROUIN-CHARTIER JP, Tremblay AJ, Bergeron J, Lamarche B, et al
    High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
    Atherosclerosis. 2018;270:26-32.
    PubMed     Text format     Abstract available


    December 2017
  11. PEK SLT, Dissanayake S, Fong JCW, Lin MX, et al
    Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
    Atherosclerosis. 2017;269:106-116.
    PubMed     Text format     Abstract available


  12. SANCHEZ-HERNANDEZ RM, Prieto-Matos P, Civeira F, Lafuente EE, et al
    Autosomal recessive hypercholesterolemia in Spain.
    Atherosclerosis. 2017;269:1-5.
    PubMed     Text format     Abstract available


    October 2017
  13. HOEKE G, Wang Y, van Dam AD, Mol IM, et al
    Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
    Atherosclerosis. 2017;267:116-126.
    PubMed     Text format     Abstract available


  14. AMROCK SM, Duell PB, Knickelbine T, Martin SS, et al
    Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry.
    Atherosclerosis. 2017;267:19-26.
    PubMed     Text format     Abstract available


    September 2017
  15. HOVLAND A, Mundal LJ, Igland J, Veierod MB, et al
    Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;266:69-73.
    PubMed     Text format     Abstract available


  16. CHRISTENSEN JJ, Ulven SM, Retterstol K, Narverud I, et al
    Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study.
    Atherosclerosis. 2017;266:48-57.
    PubMed     Text format     Abstract available


  17. KAWASHIRI MA, Nohara A, Higashikata T, Tada H, et al
    Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Atherosclerosis. 2017;265:225-230.
    PubMed     Text format     Abstract available


    August 2017
  18. GITT AK, Lautsch D, Ferrieres J, De Ferrari GM, et al
    Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Atherosclerosis. 2017;266:158-166.
    PubMed     Text format     Abstract available


  19. SCHMIDT N, Schmidt B, Dressel A, Gergei I, et al
    Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study.
    Atherosclerosis. 2017;266:24-30.
    PubMed     Text format     Abstract available


    July 2017
  20. NIKKOLA E, Ko A, Alvarez M, Cantor RM, et al
    Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family.
    Atherosclerosis. 2017;264:58-66.
    PubMed     Text format     Abstract available


  21. YANG ZH, Gordon SM, Sviridov D, Wang S, et al
    Dietary supplementation with long-chain monounsaturated fatty acid isomers decreases atherosclerosis and alters lipoprotein proteomes in LDLr(-/-) mice.
    Atherosclerosis. 2017;262:31-38.
    PubMed     Text format     Abstract available


  22. CHO I, O Hartaigh B, Gransar H, Valenti V, et al
    Prognostic implications of coronary artery calcium in the absence of coronary artery luminal narrowing.
    Atherosclerosis. 2017;262:185-190.
    PubMed     Text format     Abstract available


  23. STEINHAGEN-THIESSEN E, Stroes E, Soran H, Johnson C, et al
    The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.
    Atherosclerosis. 2017;262:146-153.
    PubMed     Text format     Abstract available


    June 2017
  24. SILVA PRS, Jannes CE, Oliveira TGM, Miname MH, et al
    Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.
    Atherosclerosis. 2017;263:257-262.
    PubMed     Text format     Abstract available


  25. SANTOS RD, Miname MH
    Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype: What do genetic defects tell us and what are the clinical implications?
    Atherosclerosis. 2017 Jun 12. pii: S0021-9150(17)30254.
    PubMed     Text format    


  26. VONGPROMEK R, Bos S, Ten Kate GR, Bujo H, et al
    Soluble LR11 associates with aortic root calcification in asymptomatic treated male patients with familial hypercholesterolemia.
    Atherosclerosis. 2017 Jun 9. pii: S0021-9150(17)30268.
    PubMed     Text format     Abstract available


  27. BEA AM, Perez-Calahorra S, Marco-Benedi V, Lamiquiz-Moneo I, et al
    Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:92-96.
    PubMed     Text format     Abstract available


  28. TERAMOTO T, Daida H, Ikewaki K, Arai H, et al
    Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
    Atherosclerosis. 2017;261:69-77.
    PubMed     Text format     Abstract available


  29. ARAI H, Yamashita S, Yokote K, Araki E, et al
    Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipida
    Atherosclerosis. 2017;261:144-152.
    PubMed     Text format     Abstract available


    May 2017
  30. HAGENSEN MK, Mortensen MB, Kjolby M, Stillits NL, et al
    Type 1 diabetes increases retention of low-density lipoprotein in the atherosclerosis-prone area of the murine aorta.
    Atherosclerosis. 2017;263:7-14.
    PubMed     Text format     Abstract available


  31. SHARIFI M, Higginson E, Bos S, Gallivan A, et al
    Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.
    Atherosclerosis. 2017 May 13. pii: S0021-9150(17)30218.
    PubMed     Text format     Abstract available


  32. MASANA L, Plana N, Perez-Calahorra S, Ibarretxe D, et al
    How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Atherosclerosis. 2017;262:107-112.
    PubMed     Text format     Abstract available


  33. BUONUOMO PS, Iughetti L, Pisciotta L, Rabacchi C, et al
    Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia.
    Atherosclerosis. 2017;262:71-77.
    PubMed     Text format     Abstract available


  34. OTHMAN RA, Myrie SB, Mymin D, Roullet JB, et al
    Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia.
    Atherosclerosis. 2017;260:27-33.
    PubMed     Text format     Abstract available


    April 2017
  35. MANGILI LC, Miname MH, Silva PRS, Bittencourt MS, et al
    Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.
    Atherosclerosis. 2017 Apr 30. pii: S0021-9150(17)30189.
    PubMed     Text format     Abstract available


  36. BOURBON M, Alves AC, Alonso R, Mata N, et al
    Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry.
    Atherosclerosis. 2017;262:8-13.
    PubMed     Text format     Abstract available


  37. HIGUCHI S, Kabeya Y, Kato K
    Visceral-to-subcutaneous fat ratio is independently related to small and large cerebrovascular lesions even in healthy subjects.
    Atherosclerosis. 2017;259:41-45.
    PubMed     Text format     Abstract available


    March 2017
  38. LI S, Wu NQ, Zhu CG, Zhang Y, et al
    Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
    Atherosclerosis. 2017;260:67-74.
    PubMed     Text format     Abstract available


  39. FUTEMA M, Cooper JA, Charakida M, Boustred C, et al
    Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC).
    Atherosclerosis. 2017;260:47-55.
    PubMed     Text format     Abstract available


    February 2017
  40. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Atherosclerosis. 2017;259:20-25.
    PubMed     Text format     Abstract available


  41. JANUS ED
    Homozygous familial hypercholesterolaemia - Early recognition and early treatment improve outcomes.
    Atherosclerosis. 2017 Feb 16. pii: S0021-9150(17)30060.
    PubMed     Text format    


  42. XIANG R, Fan LL, Lin MJ, Li JJ, et al
    The genetic spectrum of familial hypercholesterolemia in the central south region of China.
    Atherosclerosis. 2017;258:84-88.
    PubMed     Text format     Abstract available


  43. LADWIG KH, Baumert J, Marten-Mittag B, Lukaschek K, et al
    Room for depressed and exhausted mood as a risk predictor for all-cause and cardiovascular mortality beyond the contribution of the classical somatic risk factors in men.
    Atherosclerosis. 2017;257:224-231.
    PubMed     Text format     Abstract available


  44. DI COSTANZO A, D'Erasmo L, Polimeni L, Baratta F, et al
    Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage.
    Atherosclerosis. 2017;257:232-239.
    PubMed     Text format     Abstract available


    January 2017
  45. WIDHALM K, Benke IM, Fritz M, Geiger H, et al
    Homozygous familial hypercholesterolemia: Summarized case reports.
    Atherosclerosis. 2017;257:86-89.
    PubMed     Text format     Abstract available


  46. BRUCKERT E, Kalmykova O, Bittar R, Carreau V, et al
    Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Atherosclerosis. 2017;257:130-137.
    PubMed     Text format     Abstract available


  47. BOS S, Duvekot MH, Ten Kate GR, Verhoeven AJ, et al
    Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study.
    Atherosclerosis. 2017;256:62-66.
    PubMed     Text format     Abstract available


  48. NONIN S, Iwata S, Sugioka K, Fujita S, et al
    Plaque surface irregularity and calcification length within carotid plaque predict secondary events in patients with coronary artery disease.
    Atherosclerosis. 2017;256:29-34.
    PubMed     Text format     Abstract available


  49. ANDREOZZI F, Mannino GC, Perticone M, Perticone F, et al
    Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with a pro-atherogenic lipid profile.
    Atherosclerosis. 2017;256:15-20.
    PubMed     Text format     Abstract available


    December 2016
  50. DURST R, Ibe UK, Shpitzen S, Schurr D, et al
    Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Atherosclerosis. 2016;257:55-63.
    PubMed     Text format     Abstract available


  51. PANES O, Gonzalez C, Hidalgo P, Valderas JP, et al
    Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.
    Atherosclerosis. 2016;257:164-171.
    PubMed     Text format     Abstract available


  52. CHRISTENSEN JJ, Osnes LT, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;256:67-74.
    PubMed     Text format     Abstract available


    November 2016
  53. FRANCE M, Rees A, Datta D, Thompson G, et al
    HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    Atherosclerosis. 2016 Nov 5. pii: S0021-9150(16)31420.
    PubMed     Text format     Abstract available


    October 2016
  54. SETIA N, Saxena R, Arora A, Verma IC, et al
    Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.
    Atherosclerosis. 2016;255:31-36.
    PubMed     Text format     Abstract available


  55. DANCER M, Caussy C, Di Filippo M, Moulin P, et al
    Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3'UTR variant SstI.
    Atherosclerosis. 2016;255:6-10.
    PubMed     Text format     Abstract available


  56. CASULA M, Scotti L, Tragni E, Merlino L, et al
    Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016;254:172-178.
    PubMed     Text format     Abstract available


  57. OGURA M, Makino H, Kamiya C, Yoshimatsu J, et al
    Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.
    Atherosclerosis. 2016;254:179-183.
    PubMed     Text format     Abstract available


    September 2016
  58. KOSTNER K
    Coronary calcification in familial hypercholesterolemia: Not all about LDL.
    Atherosclerosis. 2016 Sep 28. pii: S0021-9150(16)31377.
    PubMed     Text format    


  59. MARTIN R, Latten M, Hart P, Murray H, et al
    Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Atherosclerosis. 2016;254:8-13.
    PubMed     Text format     Abstract available


  60. MANGILI LC, Mangili OC, Bittencourt MS, Miname MH, et al
    Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia.
    Atherosclerosis. 2016;254:73-77.
    PubMed     Text format     Abstract available


  61. ARCA M
    Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Atherosclerosis. 2016 Sep 2. pii: S0021-9150(16)31315.
    PubMed     Text format     Abstract available


    August 2016
  62. ALONSO R, Mata P, Muniz O, Fuentes-Jimenez F, et al
    PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
    Atherosclerosis. 2016 Aug 27. pii: S0021-9150(16)31306.
    PubMed     Text format     Abstract available


  63. GRENKOWITZ T, Kassner U, Wuhle-Demuth M, Salewsky B, et al
    Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Atherosclerosis. 2016;253:88-93.
    PubMed     Text format     Abstract available


    July 2016
  64. WATTS GF, Pang J, Chan DC, Brunt JN, et al
    Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.
    Atherosclerosis. 2016;252:82-87.
    PubMed     Text format     Abstract available


  65. ROETERS VAN LENNEP JE
    Knowledge equals health; why all healthcare professionals should know about familial hypercholesterolemia.
    Atherosclerosis. 2016 Jul 30. pii: S0021-9150(16)31229.
    PubMed     Text format    


  66. TORVIK K, Narverud I, Ottestad I, Svilaas A, et al
    Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;252:21-27.
    PubMed     Text format     Abstract available


  67. SCHOFIELD J, Kwok S, France M, Capps N, et al
    Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey.
    Atherosclerosis. 2016 Jul 10. pii: S0021-9150(16)30308.
    PubMed     Text format     Abstract available


  68. SJOUKE B, Defesche JC, de Randamie JS, Wiegman A, et al
    Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2016;251:263-265.
    PubMed     Text format     Abstract available


    May 2016
  69. SILVA PR, Jannes CE, Marsiglia JD, Krieger JE, et al
    Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia.
    Atherosclerosis. 2016;250:144-150.
    PubMed     Text format     Abstract available


  70. NARDIN M, Verdoia M, Schaffer A, Barbieri L, et al
    Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography.
    Atherosclerosis. 2016;250:114-121.
    PubMed     Text format     Abstract available


  71. BANERJEE Y, Santos RD, Al-Rasadi K, Rizzo M, et al
    Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Atherosclerosis. 2016;248:62-75.
    PubMed     Text format     Abstract available


  72. ZHOU T, Ding JW, Wang XA, Zheng XX, et al
    Long noncoding RNAs and atherosclerosis.
    Atherosclerosis. 2016;248:51-61.
    PubMed     Text format     Abstract available


  73. PAN L, Yang Z, Wu Y, Yin RX, et al
    The prevalence, awareness, treatment and control of dyslipidemia among adults in China.
    Atherosclerosis. 2016;248:2-9.
    PubMed     Text format     Abstract available


    April 2016
  74. KRAUZOVA E, Kracmerova J, Rossmeislova L, Malisova L, et al
    Acute hyperlipidemia initiates proinflammatory and proatherogenic changes in circulation and adipose tissue in obese women.
    Atherosclerosis. 2016;250:151-157.
    PubMed     Text format     Abstract available


  75. HUANG Y, Xu M, Xie L, Wang T, et al
    Obesity and peripheral arterial disease: A Mendelian Randomization analysis.
    Atherosclerosis. 2016;247:218-24.
    PubMed     Text format     Abstract available


  76. KOLODZIEJCZAK M, Navarese EP
    Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
    Atherosclerosis. 2016;247:189-92.
    PubMed     Text format     Abstract available


    March 2016
  77. MICKIEWICZ A, Chmara M, Futema M, Fijalkowski M, et al
    Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland.
    Atherosclerosis. 2016;249:52-58.
    PubMed     Text format     Abstract available


  78. ARAI H, Teramoto T, Daida H, Ikewaki K, et al
    Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016 Mar 25. pii: S0021-9150(16)30092.
    PubMed     Text format     Abstract available


  79. RALLIDIS LS, Triantafyllis AS, Tsirebolos G, Katsaras D, et al
    Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
    Atherosclerosis. 2016;249:17-21.
    PubMed     Text format     Abstract available


  80. RAAL FJ, Sjouke B, Hovingh GK, Isaac BF, et al
    Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
    Atherosclerosis. 2016 Mar 11. pii: S0021-9150(16)30084.
    PubMed     Text format     Abstract available


  81. STEFFENSEN LB, Conover CA, Bjorklund MM, Ledet T, et al
    Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
    Atherosclerosis. 2016;248:36-43.
    PubMed     Text format     Abstract available


  82. ROTLLAN N, Price N, Pati P, Goedeke L, et al
    microRNAs in lipoprotein metabolism and cardiometabolic disorders.
    Atherosclerosis. 2016;246:352-60.
    PubMed     Text format     Abstract available


  83. EL TAHLAWI M, Sakrana A, Elmurr A, Gouda M, et al
    The relation between coronary tortuosity and calcium score in patients with chronic stable angina and normal coronaries by CT angiography.
    Atherosclerosis. 2016;246:334-7.
    PubMed     Text format     Abstract available


  84. CAUSSY C, Charriere S, Meirhaeghe A, Dallongeville J, et al
    Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.
    Atherosclerosis. 2016;246:280-6.
    PubMed     Text format     Abstract available


  85. PEDERSEN LR, Olsen RH, Anholm C, Walzem RL, et al
    Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial.
    Atherosclerosis. 2016;246:221-8.
    PubMed     Text format     Abstract available


  86. ESCATE R, Padro T, Badimon L
    LDL accelerates monocyte to macrophage differentiation: Effects on adhesion and anoikis.
    Atherosclerosis. 2016;246:177-86.
    PubMed     Text format     Abstract available


  87. POKHAREL Y, Steinberg L, Chan W, Akeroyd JM, et al
    Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
    Atherosclerosis. 2016;246:115-20.
    PubMed     Text format     Abstract available


  88. SCHWEITZER M, Makhoul S, Paliouras M, Beitel LK, et al
    Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Atherosclerosis. 2016;246:78-86.
    PubMed     Text format     Abstract available


    February 2016
  89. AMOR AJ, Catalan M, Perez A, Herreras Z, et al
    Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis.
    Atherosclerosis. 2016;247:161-169.
    PubMed     Text format     Abstract available


  90. SANNA C, Stephenne X, Revencu N, Smets F, et al
    Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
    Atherosclerosis. 2016;247:97-104.
    PubMed     Text format     Abstract available


  91. HERNANDEZ-MIJARES A, Banuls C, Rovira-Llopis S, Diaz-Morales N, et al
    Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
    Atherosclerosis. 2016;247:40-47.
    PubMed     Text format     Abstract available


    January 2016
  92. BAILA-RUEDA L, Perez-Ruiz MR, Jarauta E, Tejedor MT, et al
    Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
    Atherosclerosis. 2016;246:202-207.
    PubMed     Text format     Abstract available


  93. ZHENG L, Wu T, Zeng C, Li X, et al
    SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.
    Atherosclerosis. 2016;244:179-87.
    PubMed     Text format     Abstract available


  94. FARNIER M, Jones P, Severance R, Averna M, et al
    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Atherosclerosis. 2016;244:138-46.
    PubMed     Text format     Abstract available


    December 2015
  95. RASMUSSEN KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R, et al
    Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population.
    Atherosclerosis. 2015;246:63-70.
    PubMed     Text format     Abstract available


  96. BESSELING J, Huijgen R, Martin SS, Hutten BA, et al
    Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia.
    Atherosclerosis. 2015;246:1-6.
    PubMed     Text format     Abstract available


  97. NIIMI M, Yang D, Kitajima S, Ning B, et al
    ApoE knockout rabbits: A novel model for the study of human hyperlipidemia.
    Atherosclerosis. 2015;245:187-193.
    PubMed     Text format     Abstract available


    October 2015
  98. BASU A, Jenkins AJ, Zhang Y, Stoner JA, et al
    Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.
    Atherosclerosis. 2015;244:93-100.
    PubMed     Text format     Abstract available


  99. SCHOFIELD J, Bhatnagar D
    The impact of gestational hypercholesterolaemia on origins of disease.
    Atherosclerosis. 2015 Oct 22. pii: S0021-9150(15)30160.
    PubMed     Text format    


  100. RATHOUSKA J, Jezkova K, Nemeckova I, Nachtigal P, et al
    Soluble endoglin, hypercholesterolemia and endothelial dysfunction.
    Atherosclerosis. 2015;243:383-388.
    PubMed     Text format     Abstract available


    September 2015
  101. THOMPSON GR, Seed M, Naoumova RP, Neuwirth C, et al
    Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes.
    Atherosclerosis. 2015;243:328-333.
    PubMed     Text format     Abstract available


  102. VALLEJO-VAZ AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, et al
    Familial hypercholesterolaemia: A global call to arms.
    Atherosclerosis. 2015;243:257-259.
    PubMed     Text format    


  103. IRAWATI D, Mamo JC, Soares MJ, Slivkoff-Clark KM, et al
    Hypertriglyceridemic subjects exhibit an accumulation of small dense chylomicron particles in the fasting state.
    Atherosclerosis. 2015;243:236-241.
    PubMed     Text format     Abstract available


  104. NARVERUD I, van Lennep JR, Christensen JJ, Versmissen J, et al
    Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia.
    Atherosclerosis. 2015;243:155-160.
    PubMed     Text format     Abstract available


  105. SHIN DG, Han SM, Kim DI, Rhee MY, et al
    Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;243:53-58.
    PubMed     Text format     Abstract available


  106. BARKAS F, Elisaf M, Milionis H
    Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2015;243:60-64.
    PubMed     Text format     Abstract available


    August 2015
  107. YU HH, Chen PC, Yang YH, Wang LC, et al
    Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
    Atherosclerosis. 2015;243:11-18.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: